Keymed Biosciences Inc.
HKSE: 2162.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bo Chen
- Employees
- 1,258
- Headquarters
- Chengdu, China
- IPO year
- 2021
- Market cap
- HK$21.2B
- Website
- https://www.keymedbio.com
Loading 2162…
Loading profile data…Frequently asked questions about 2162
What does Keymed Biosciences Inc. (2162.HK) do?
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic ob...
Where does 2162.HK trade?
Keymed Biosciences Inc. (2162.HK) trades on the Hong Kong Stock Exchange.
What sector is 2162.HK in?
Keymed Biosciences Inc. (2162.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Keymed Biosciences Inc.?
Bo Chen is the chief executive officer of Keymed Biosciences Inc. (2162.HK).
Where is Keymed Biosciences Inc. headquartered?
Keymed Biosciences Inc. is headquartered in China.
Does 2162.HK pay a dividend?
Keymed Biosciences Inc. (2162.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2162.HK go public?
Keymed Biosciences Inc. (2162.HK) completed its initial public offering in 2021.